img

Global Compounding Chemotherapy Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034


Published on: 2024-01-04 | No of Pages : 411 | Industry : Medical Care

Publisher : GRD Survey | Format : PDF

Global Compounding Chemotherapy Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034

Executive Summary

According to GRD Survey data, the global Compounding Chemotherapy market is estimated at million US$ in 2021 and is expected to million US$ by the end of 2028, growing at a CAGR of % in the forecast period from 2022 to 2028.

This report studies the Compounding Chemotherapy market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Compounding Chemotherapy in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Gravimetric Automated Compounding Device (Weight-Based)
Volumetric Automated Compounding Device (Volume-Based)

Market Snapshot, By Application
Breast Cancer
Blood Cancer
Prostate Cancer
Gastrointestinal Cancer
Respiratory/Lung Cancer
Others

Main Market Players Analyzed in this report, including
The Metrix Company
Sterline S.R.L.
Pfizer Inc.
Omnicell
Millers Pharmacy
Loccioni
Icon group
Grifols SA
Equashield
Dedalus Group
Comecer S.P.A.
Braun Melsungen AG
Baxter
Arxium
Added Pharma

The study objectives of this report are
To study and analyze the global Compounding Chemotherapy market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Compounding Chemotherapy market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Compounding Chemotherapy manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Compounding Chemotherapy market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Compounding Chemotherapy submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Compounding Chemotherapy are as follows
History Year2016-2020
Base Year2020
Estimated Year2021
Forecast Year 2021 to 2027

This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Global Compounding Chemotherapy Industry Outlook 2022: Overview, Opportunities, Key Companies and Forecast to 2028.pdf

List of Figure

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Compounding Chemotherapy Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Compounding Chemotherapy Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Compounding Chemotherapy

3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Breast Cancer
3.2.2 Major Buyers in Blood Cancer

4 Market Segment: by Type
4.1 Compounding Chemotherapy Type Introduction
4.1.1 Gravimetric Automated Compounding Device (Weight-Based)
4.1.2 Volumetric Automated Compounding Device (Volume-Based)
4.2 Global Compounding Chemotherapy Revenue by Type 2016-2021

5 Market Segment: by Application
5.1 Compounding Chemotherapy Type Introduction
5.1.1 Breast Cancer
5.1.2 Blood Cancer
5.1.3 Prostate Cancer
5.1.3 Gastrointestinal Cancer
5.1.4 Respiratory/Lung Cancer
5.1.5 Others
5.2 Global Compounding Chemotherapy Revenue by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Compounding Chemotherapy Market by Region
6.2 North America Compounding Chemotherapy Market 2016-2021
6.3 Europe Compounding Chemotherapy Market 2016-2021
6.4 Asia Pacific Compounding Chemotherapy Market 2016-2021
6.5 South America Compounding Chemotherapy Market 2016-2021
6.6 Middle East and Africa Compounding Chemotherapy Market 2016-2021

7 North America
7.1 North America Compounding Chemotherapy Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Compounding Chemotherapy Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Compounding Chemotherapy Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Compounding Chemotherapy Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Compounding Chemotherapy Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 The Metrix Company
12.1.1 The Metrix Company Company Information
12.1.2 The Metrix Company Compounding Chemotherapy Product Portfolio, Specification and Application
12.1.3 The Metrix Company Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.1.4 The Metrix Company Key Development
12.2 Sterline S.R.L.
12.2.1 Sterline S.R.L. Company Information
12.2.2 Sterline S.R.L. Compounding Chemotherapy Product Portfolio, Specification and Application
12.2.3 Sterline S.R.L. Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.2.4 Sterline S.R.L. Key Development
12.3 Pfizer Inc.
12.3.1 Pfizer Inc. Company Information
12.3.2 Pfizer Inc. Compounding Chemotherapy Product Portfolio, Specification and Application
12.3.3 Pfizer Inc. Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.3.4 Pfizer Inc. Key Development
12.4 Omnicell
12.4.1 Omnicell Company Information
12.4.2 Omnicell Compounding Chemotherapy Product Portfolio, Specification and Application
12.4.3 Omnicell Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.4.4 Omnicell Key Development
12.5 Millers Pharmacy
12.5.1 Millers Pharmacy Company Information
12.5.2 Millers Pharmacy Compounding Chemotherapy Product Portfolio, Specification and Application
12.5.3 Millers Pharmacy Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.5.4 Millers Pharmacy Key Development
12.6 Loccioni
12.6.1 Loccioni Company Information
12.6.2 Loccioni Compounding Chemotherapy Product Portfolio, Specification and Application
12.6.3 Loccioni Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.6.4 Loccioni Key Development
12.7 Icon group
12.7.1 Icon group Company Information
12.7.2 Icon group Compounding Chemotherapy Product Portfolio, Specification and Application
12.7.3 Icon group Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.7.4 Loccioni Key Development
12.9 Equashield
12.9.1 Equashield Company Information
12.9.2 Equashield Compounding Chemotherapy Product Portfolio, Specification and Application
12.9.3 Equashield Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.9.4 Equashield Key Development
12.8 Grifols SA
12.8.1 Grifols SA Company Information
12.8.2 Grifols SA Compounding Chemotherapy Product Portfolio, Specification and Application
12.8.3 Grifols SA Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.8.4 Grifols SA Key Development
12.11 Comecer S.P.A.
12.11.1 Comecer S.P.A. Company Information
12.11.2 Comecer S.P.A. Compounding Chemotherapy Product Portfolio, Specification and Application
12.11.3 Comecer S.P.A. Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.11.4 Comecer S.P.A. Key Development
12.12 Braun Melsungen AG
12.12.1 Braun Melsungen AG Company Information
12.12.2 Braun Melsungen AG Compounding Chemotherapy Product Portfolio, Specification and Application
12.12.3 Braun Melsungen AG Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.12.4 Braun Melsungen AG Key Development
12.13 Baxter
12.13.1 Baxter Company Information
12.13.2 Baxter Compounding Chemotherapy Product Portfolio, Specification and Application
12.13.3 Baxter Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.13.4 Baxter Key Development
12.14 Arxium
12.14.1 Arxium Company Information
12.14.2 Arxium Compounding Chemotherapy Product Portfolio, Specification and Application
12.14.3 Arxium Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.14.4 Arxium Key Development
12.15 Added Pharma
12.15.1 Added Pharma Company Information
12.15.2 Added Pharma Compounding Chemotherapy Product Portfolio, Specification and Application
12.15.3 Added Pharma Compounding Chemotherapy Revenue and Gross Margin (2019-2021)
12.15.4 Added Pharma Key Development

13 Global Compounding Chemotherapy Market Forecast by Region by Type and by Application
13.1 Global Compounding Chemotherapy Revenue Forecast 2022-2027
13.2 Global Compounding Chemotherapy Forecast by Regions
13.3 Global Compounding Chemotherapy Forecast by Type
13.4 Global Compounding Chemotherapy Forecast by Application

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer